Related Experiment Videos
[Laboratory and clinical studies on cefteram pivoxil in the field of pediatrics]
1Department of Pediatrics, Anjo Kosei Hospital.
Insights
This study evaluated cefteram pivoxil, a new antibiotic, in pediatric patients. Cefteram demonstrated potent antibacterial activity and high clinical efficacy with minimal side effects, showing promise for treating pediatric infections.
Area of Science:
- Pediatric infectious diseases
- Pharmacokinetics and pharmacodynamics of antibiotics
- Antimicrobial resistance
Context:
- Pediatric infectious diseases pose a significant health burden.
- Novel antibiotics are needed to combat evolving bacterial resistance.
- Cefteram pivoxil is a new cephem antibiotic for pediatric use.
Purpose:
- To evaluate the pharmacokinetics of cefteram pivoxil in pediatric patients.
- To assess the in vitro antibacterial activity of cefteram against clinical isolates.
- To determine the clinical efficacy and safety of cefteram pivoxil in treating pediatric infections.
Summary:
- Cefteram pivoxil showed favorable serum and urinary concentrations in pediatric patients.
- In vitro studies indicated cefteram's potent activity against Gram-negative and Gram-positive bacteria, outperforming cefaclor and cephalexin.
- Clinical trials demonstrated 100% clinical efficacy and 70% bacteriological efficacy in pediatric patients with acute infections, with good tolerability.
Impact:
- Cefteram pivoxil represents a promising new therapeutic option for pediatric infectious diseases.
- The findings support the use of cefteram pivoxil in pediatric clinical practice.
- Further research may explore broader applications and long-term outcomes of cefteram pivoxil.
Abstract:
Laboratory and clinical studies on cefteram pivoxil(cefteram) a new cephem antibiotic, were carried out in the field of pediatrics. The results obtained are summarized as follows: 1. Serum concentrations, urinary concentrations and urinary recovery rates of cefteram (CFTM) were determined upon oral administration after meal of cefteram pivoxil (CFTM-PI) at doses of 3 mg/kg granules in 2 cases and 6 mg/kg granules in 2. Peak serum levels of CFTM were obtained at 3 hours in 2 cases and 4 hours in 2 cases after administration of the drug with a range of 0.74-2.2 micrograms/ml with half-lives of 0.77-3.62 hours. Urinary recovery rates in 8 hours after administration ranged from 9.6-23.0%. 2. MICs of CFTM against 22 clinical isolates (Streptococcus pyogenes 4 strains, Streptococcus pneumoniae 4, Staphylococcus aureus 2, Branhamella catarrhalis 1, Haemophilus influenzae 8, Haemophilus parainfluenzae 1, and Escherichia coli 2) were compared with those of cefaclor (CCL), cephalexin (CEX), and ampicillin (ABPC). The antibacterial activity of CFTM was superior to those of CCL and CEX, and was superior against Gram-negative rods and equal against Gram-positive cocci to those of ABPC. 3. Twenty-six pediatric patients with acute infectious diseases (scarlet fever 3 cases, tonsillitis 7, epiglottitis 1, bronchitis 5, pneumonia 5, urinary tract infection 3, cervical lymphadenitis 2) were treated with CFTM-PI at daily doses of 9.3-15.3 mg/kg t.i.d. as a rule. The efficacy rates were 100% clinically and 70% bacteriologically. 4. Side effects or abnormal laboratory test values were not observed except for an increased platelet count in 1 case.